Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

KenneyP.A.; WoodC.G.

首页> 外文期刊>European urology >Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

【24h】

Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

机译：回复：阿西替尼与索拉非尼在晚期肾细胞癌（AXIS）中的比较有效性：一项随机的3期临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Experts' summary:AXIS is an international randomized phase 3 trial comparing axitinib versus sorafenib as second-line therapy in patients with metastatic renal cell carcinoma (RCC). Axitinib is a potent inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3 and appears to be more selective than sunitinib or sorafenib [1].

机译：专家总结：AXIS是一项国际随机3期试验，比较了阿昔替尼和索拉非尼作为转移性肾细胞癌（RCC）患者的二线治疗。阿昔替尼是一种有效的血管内皮生长因子受体（VEGFRs）1、2和3的抑制剂，似乎比舒尼替尼或索拉非尼更具选择性[1]。

著录项

来源
《European urology》 |2012年第1期|共2页
作者
KenneyP.A.; WoodC.G.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial [J] . KenneyP.A., WoodC.G. European urology . 2012,第1期

机译：回复：阿西替尼与索拉非尼在晚期肾细胞癌（AXIS）中的比较有效性：一项随机的3期临床试验
2. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial [J] . B Escudier, M D Michaelson, R J Motzer, British Journal of Cancer . 2014,第12期

机译：阿昔替尼与索拉非尼在晚期肾细胞癌中的作用：一项随机III期临床试验先前治疗的亚分析
3. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial [J] . MotzerR.J., EscudierB., TomczakP., The lancet oncology . 2013,第6期

机译：阿昔替尼vs索拉非尼作为晚期肾细胞癌的二线治疗：总体生存分析和一项随机3期试验的更新结果
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Sexuality and gynaecological cancer: A randomised control trial to evaluate the effectiveness of a group psychoeducational intervention in improving the sexual health of women with gynaecological cancer treated with radiotherapy [D] . Jeffries, Sherryl Anne 2003

机译：性与妇科癌症：一项随机对照试验，旨在评估团体心理教育干预措施对经放射治疗的妇科癌症妇女改善性健康的有效性
6. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial [O] . B Escudier, M D Michaelson, R J Motzer, 2014

机译：阿昔替尼与索拉非尼在晚期肾细胞癌中的作用：一项随机III期临床试验先前治疗的亚分析
7. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial [O] . B Escudier, M D Michaelson, R J Motzer, 2014

机译：Axitinib与索拉非尼在晚期肾细胞癌中：来自随机阶段III试验的先前治疗的subanalyses

Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅